UIC enrolls patients to second trial to assess potential COVID-19 cure
Category: #health  By Saipriya Iyer  Date: 2020-05-19
  • share
  • Twitter
  • Facebook
  • LinkedIn

UIC enrolls patients to second trial to assess potential COVID-19 cure

The University of Illinois at Chicago, has reportedly announced that it has started the patient enrolling process for a second clinical study to assess the efficacies of the drug, remdesivir, as an effective treatment for the coronavirus.

Funded by the NIAID (National Institute of Allergy and Infectious Disease), this placebo-controlled, international, randomized clinical trial would study the antiviral drug by combining it with baricitinib, an anti-inflammatory drug that is usually used to treat rheumatoid arthritis.

This clinical trial comes on the heels of the Adaptive COVID-19 Treatment Trial conducted by NIAID, where the outcomes demonstrated that patients who were given remdesivir recovered quicker than those who were under the control group and given a placebo.

Dr. Richard Novak, Prof. and the Head of Infectious Disease, as well as the Principal Investigator of UIC trial, stated that few patients with more serious coronavirus cases experience ARDS (acute respiratory distress syndrome), which is characterized by rapid breathing and shortness of breath and due to lung inflammation. 

Dr. Novak further added that since baricitinib helps reduce inflammation, it can be assessed to see if it helps alleviate ARDS by reducing the inflammatory response of the body to the infection, and offer an advantage to coronavirus patients that develop severe complications. The team expects that most of the patients undergoing the trial via UIC would be members of the communities that are impacted by the coronavirus.

In the clinical trial, all patients who will be enrolled for the test from the University of Illinois Hospital, will receive remdesivir, but half of these patients will also be given baricitinib. The other half of enrolled patients will receive a baricitinib placebo. Neither the doctors and researchers nor the patients would know which patient is given baricitinib.

To be eligible to enroll for this clinical trial, patients must be hospitalized and diagnosed with confirmed COVID-19 infection. Additionally, they also need to have lung-related complications, including abnormal chest X-rays, need to have a supplemental oxygen supply, or some illness that needs mechanical ventilation.

As per the National Institutes of Health, the study investigators expect to enroll 1,000 participants, which also includes the patients participating in UIC’s study.

 

Source credit: https://www.newswise.com/coronavirus/new-remdesivir-trial-at-uic-tests-drug-in-combination-with-baricitinib/?article_id=731743



About Author

Saipriya Iyer

Email: [email protected]   

Saipriya Iyer

Saipriya Iyer develops content for Market Size Forecasters, Algosonline, and myriad other platforms. A computer engineer by profession, she ventured into the field of writing for the love of playing with words. Having had a previous experience of 3 years under her bel...

Read More

More News By Saipriya Iyer

AdaptHealth enters definitive deals to acquire Solara & ActivStyle
AdaptHealth enters definitive deals to acquire Solara & ActivStyle
By Saipriya Iyer

AdaptHealth Corp. has recently entered two separate definitive agreements for the acquisition of Solara Medical Supplies, LLC and ActivStyle, Inc. AdaptHealth is a leading home medical supplies, equipment, and other re...

Ambani’s JioMart unveils a new website to deliver orders across India
Ambani’s JioMart unveils a new website to deliver orders across India
By Saipriya Iyer

Jio Platforms, the top telecom operator along with Jio Retail, which is the top retail chain has recently unveiled JioMart’s new website and has begun taking orders in a large amount from tier 1, tier 2 and metro c...

Omada enters $30M acquisition deal with digital health company Physera
Omada enters $30M acquisition deal with digital health company Physera
By Saipriya Iyer

Omada Health, which has raised nearly $57 million in funding, has reportedly acquired a digital health company, Physera. It provides remote physical therapy to its customers.

The co...